Skip to main content
Equibles
LXRX logo

LXRX · Lexicon Pharmaceuticals, Inc.

Track LXRX — free

Use LXRX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about LXRX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.30 -0.03 (-1.08%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.03B
Shares
444.96M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.32 Open$2.30 Day$2.30–2.34 52W close$1.07–2.64 Avg vol 30d2.7M Short int32.7M · 7.4% float · 10.9d Short vol53% Last earningsAug 6, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Nov 6, 2026 Est · unconfirmed · in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 14.5 · calm Equity put/call 0.39
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +32%
      above
      Price vs 50-day avg +0%
      above
      RSI (14) 50
      neutral
      MACD trend Negative
      52-week position 80%
      mid-range
      Momentum
      relative strength
      Very Strong
      1-month return −1%
      trailing
      6-month return +36%
      trailing
      YTD return +102%
      this year
      Relative strength +21%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $2 › 200d $2 — 50d above 200d
      Institutional flow Accumulating
      +9% holders QoQ · +43 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      7.36% of float · ▼ -0.2% MoM · 10.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      149 holders — near 3-yr high, broad support
      Squeeze score 71
      high risk · 0–100
      Fundamentals
      Strong
      Revenue growth +60%
      Y/Y
      EPS growth +78%
      Y/Y
      Free cash flow $-67.9M
      Balance sheet $19.7M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 78%
      annualized · 1-yr
      Max drawdown −34%
      past year
      ATR 5.3%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the Earnings Call filed Jun 30, 2026
      Operating expenses · 2026 $100M – $110M
      R&D · 2026 $63M – $68M
      SG&A · 2026 $37M – $42M
      Prior guidance period ended · from the Earnings Call filed Jun 30, 2025
      Total operating expenses · full year 2025 $105M – $115M
      R&D expenses · full year 2025 $70M – $75M
      SG&A expenses · full year 2025 $35M – $40M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +32% Bullish
      Price vs 50-day avg
      +0% Bullish
      RSI (14)
      50 Neutral
      MACD trend
      Negative Bearish
      52-week position
      80% Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $2 › 200d $2 — 50d above 200d
      Institutional flow Accumulating
      +9% holders QoQ · +43 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      7.36% of float · ▼ -0.2% MoM · 10.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      149 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $1 Now $2 · 80% Range high $3
      vs 200-day avg +32% vs 50-day avg +0%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      LXRX
      Lexicon Pharmaceuticals, Inc.
      this stock
      		$1.03B +101.7% +60.2% — 7.4%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $138.72B +20.8% +46.2% 31.9 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $81.27B +4.6% +20.8% 20.2 2.3%
      ARGX
      Argenx SE
      		 $65.12B +25.9% — — 1.9%
      CSLLY
      Csl Ltd
      		 $59.92B — — — 0.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      149
      % held
      82.3%
      Net QoQ
      +41.1M sh
      Top holder
      Artal Group S.A.
      Held Float
      View
      Held by Funds
      Fund positions
      69
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      32.7M
      Days to cover
      10.9d
      Change
      -75.7K sh
      View
      Short Volume
      Short vol %
      53%
      As of
      Aug 27, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      288
      Value
      $674
      As of
      Jul 31, 2026
      View
      Off-Exchange
      Off-exchange %
      43.6%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $49.8M
      Net income (FY)
      $-50.3M
      EPS diluted
      $-0.14
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 6, 2026
      This year
      13
      View
      Proposed Sales
      Value
      $480.0K
      Shares
      300.0K
      Filed
      Aug 15, 2024
      View
      Exempt Offerings
      Offering
      $59.2M
      Filed
      Feb 17, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 6, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      LXRX +6.4% -0.9% +35.7% +0.4% +101.7%
      SPY +1.1% +4.0% +14.7% +3.2% +13.1%
      vs SPY +5.3% -4.8% +21.0% -2.8% +88.7%
      Key facts CIK 1062822 CUSIP 528872302 13F (30d) 134 filings 133 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)